Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Quris Technologies

Request full access

An artificial intelligence innovator that is disrupting the drug development process

Tel Aviv-Yafo, IsraelFounded 2019Biotech & Life Sciences

About Quris Technologies

Quris Technologies operates at the intersection of biotechnology and artificial intelligence, aiming to de-risk and expedite the drug development process. Founded in 2020 by CEO Dr. Isaac Bentwich and CTO Yossi Haran, the company maintains dual headquarters in Boston, USA, and Tel Aviv, Israel. Dr. Bentwich, a physician and seasoned entrepreneur, has a track record of founding successful bio-AI technology companies, including Rosetta Genomics. His work in genomics, specifically the discovery of hundreds of novel microRNA genes, laid the conceptual groundwork for Quris's integrated Bio-AI approach.

The company's core offering is its Bio-AI Clinical Prediction Platform, which forecasts the clinical safety and efficacy of new drug candidates before they enter human trials. This addresses a major pain point in the pharmaceutical industry, where a high percentage of drugs fail in clinical trials, leading to significant financial losses. The platform integrates several technologies: miniaturized "Patients-on-a-Chip," next-generation nano-sensors, and machine learning algorithms. It tests thousands of drug compounds on these chips, which contain miniaturized human organs grown from stem cells, reflecting a broad genomic diversity through a partnership with the New York Stem Cell Foundation (NYSCF). The data generated from these automated experiments continuously trains the AI models to improve their predictive accuracy, a process protected by 18 granted and pending patents.

Quris serves pharmaceutical and biotechnology firms, providing services to improve their drug candidate selection. A notable collaboration includes a multi-million dollar agreement with Merck KGaA to assess the platform's ability to identify liver toxicity risks. The business model has three pillars: offering prediction services to pharma companies, developing its own pipeline of drugs, and exploring personalized drug safety applications. The company is initially focusing on rare genetic diseases, such as Fragile X syndrome, which are difficult to model using traditional animal testing. To date, Quris has secured $37 million in seed funding from investors including SoftBank Vision Fund 2, GlenRock Capital, iAngels, and Welltech Ventures.

Source: Dealroom company data

At a glance

Status
Operational
Employees
41
Open positions
None listed
Dealroom signal
62.8/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Drug Development, Microfluidics, Core AI, Spinout, Tech for Biotech and Pharma
Technology
Artificial Intelligence, Deep Tech, Machine Learning
Business model
Manufacturing
Client focus
B2B
Investment activity
1 company, latest Oct 2024
Capital deployed
—
Preferred round
ACQUISITION

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SEED✓Equity / VC Jul 2023 $600K $95M Undisclosed —
SEED✓Equity / VC Dec 2022 $9M $95M Well-Tech Ventures · GlenRock Israel · iAngels · SoftBank ↗
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Quris Technologies website traffic

Latest recorded traffic for Quris Technologies is 3.6K monthly website visits, up 140% over the last three months. Quris Technologies's team declined 16.3% over the past year.

Latest monthly visits3.6K 3-month web change+140% 1-year team growth-16.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Quris Technologies in the Tel Aviv-Yafo ecosystem

Live from Dealroom

The Quris Technologies office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

13 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed7 investors entered at this stage

  • Judith Richter
  • Kobi Richter
  • Moshe Yanai
  • Well-Tech Ventures
  • iAngels
  • GlenRock Israel
  • SoftBank

Other known investors6 additional known investors

  • University of Pittsburgh
  • Fusion VC
  • Guy Katsovich
  • Max Burger
  • PI Impact
  • Tau Capital
Team profiled 7 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See Quris Technologies’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.